Small-Dose Intradermal Mpox Vaccine Worked Well
Earlier this year, there was a rush to vaccinate as many high-risk people as possible against what then was called monkeypox. The hope was that a vaccine approved in 2019 would be effective against the growing outbreak. New research suggests the vaccine was very effective, even at lower doses and with a different mode of administration. Read more.

Shingles Linked to Higher Risk of Cardiovascular Events
Avoiding a painful rash and other well-known side effects is not the only reason to be vaccinated to avoid getting shingles. A new study found that those who had been diagnosed with herpes zoster infection had a 30% increased risk of a major cardiovascular event and that risk persisted for more than a decade after the rash resolved. Read more.

Three-Dose HEPLISAV-B Fully Protected Adults With HIV
Even though hepatitis B vaccines have been approved for 5 years, their effectiveness in adults with HIV has remained unclear. Adults with HIV were fully protected by a three-dose course of the hepatitis B vaccine, HEPLISAV-B, even if they had never been vaccinated against or infected with the hepatitis B virus in the past, according to a new study. Read more.